Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)

NCT03847090 is registered in ClinicalTrials.gov with Allena Pharmaceuticals as lead sponsor.

NCT NCT03847090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03847090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
Lead sponsor
Allena Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
August 26, 2019
Completion date
May 19, 2022
Enrollment
92 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

enteric hyperoxaluria